cell.com· Anguraj Sadanandam, Alice C. O’Farrell, Ian S. Miller, P.S. Hari, Adrian Lärkeryd, Tom Venken, Ingrid Arijs, Eugenia R. Zanella, Francesca Cottino, Marika Pinnelli, Valentina Vurchio, Elena Grassi, Aoife Nolan, Niraj Khemka, Michael Fichtner, Gift Nyamundanda, Zak Kinsella, Maxime Meylan, Liam P. Shiels, Colum Connolly, Janick Selves, Nadja M. Meindl-Beinker, Raquel Comas Navarro, Elena Elez, Frank A. Lincoln, Chanthirika Ragulan, Orla Casey, Verena Murphy, Josep Tabernero, Walter Kolch, Matthias P. Ebert, Raquel Perez-Lopez, Florence Monville, Dirk Fey, Joern Lewin, Jonathan Briody, Kathleen Bennett, Enrique J. Arenas, Joaquín Arribas, David Matallanas, Darran P. O’Connor, Alexander Kel, Catherine Sautès-Fridman, Wolf H. Fridman, Bart Ghesquière, Paolo Nuciforo, Diether Lambrechts, Livio Trusolino, Jochen H.M. Prehn, Rodrigo Dienstmann, Annette T. Byrne, the COLOSSUS consortium·· 19 hours agoPickScore67
Multiomic characterization of microsatellite-stable colorectal cancer reveals distinct biology and targetable vulnerabilities
In brief
Sadanandam et al. integrated multiomic, single-cell, and clinical data from about 2,000 microsatellite-stable colorectal cancers (about 4,500 multiomic profiles and 195,246 cells/nuclei), identifying replication stress, right-sided tumors, glutaminolysis, and MYC-E2F epigenetic programs as key biological features. They identified FAK, PDK1/2, and proteasome inhibition combined with trametinib as potential therapeutic strategies.
Why it matters
Integrated multiomic and single-cell data from 2,000 MSS colorectal cancers identify key features and potential combination strategies with trametinib.
Source: cell.com · cell.com